BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2016 3:43:00 PM | Browse: 1434 | Download: 2152
 |
Received |
|
2016-07-09 12:16 |
|
Peer-Review Started |
|
2016-07-12 19:42 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-08-02 17:34 |
|
Revised |
|
2016-08-25 05:02 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-09-21 15:02 |
|
Second Decision by Editor-in-Chief |
|
2016-09-21 15:29 |
|
Final Decision by Editorial Office Director |
|
2016-09-28 18:56 |
|
Articles in Press |
|
2016-09-28 18:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-11-01 10:13 |
|
Publish the Manuscript Online |
|
2016-11-06 15:43 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Angela C Baird, Dominic Mallon, Graham Radford-Smith, Julien Boyer, Thierry Piche, Susan L Prescott, Ian C Lawrance and Meri K Tulic |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Meri K Tulic, PhD, INSERM, CR1, Professor, Mediterranean Center for Molecular Medicine (C3M)-INSERM U1065, Team 12, Batiment Archimed, 151 route Saint-Antoine de Ginestiere, 06204 Nice,
France. meri.tulic@unice.fr
|
| Key Words |
Ulcerative colitis; Innate immunity; Anti-tumor necrosis factor therapy; Toll-like receptor; IRAK4; Inflammatory bowel disease |
| Core Tip |
anti-tumor necrosis factor (TNF) therapy is effective in approximately 60% of ulcerative colitis (UC) patients. Currently we do not know which patients are likely to benefit from this costly treatment. Here we show that differences in innate immune function [measured by patients response to toll-like-receptor (TLR), TLR agonists] exist between UC responders and non-responders. Differences exist in (1) content of immune and regulatory cells in their blood; (2) capacity of their cells to produce cytokines; and (3) in their signalling following TLR activation. Serological measure of TLR function may prove to be a useful tool in clinic to predict patient’s response to anti-TNF treatment. |
| Publish Date |
2016-11-06 15:43 |
| Citation |
Baird AC, Mallon D, Radford-Smith G, Boyer J, Piche T, Prescott SL, Lawrance IC, Tulic MK. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. World J Gastroenterol 2016; 22(41): 9104-9116 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i41/9104.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i41.9104 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
